aTyr Pharma ATYR Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$10.79M+27.5% | -$13.96M+6.7% | -$25.75M-49.2% | -$19.53M-19.8% | -$14.88M+3.9% | ||
| $162K-3.0% | $166K-5.1% | $165K-7.3% | $166K-6.2% | $167K-6.2% | ||
| $1.31M+11.0% | $1.21M+56.8% | $1.31M+73.8% | $1.31M+79.5% | $1.18M+59.2% | ||
| -$3.47M+19.8% | -$536K— | $18K— | $4.81M+215% | -$4.32M-1,796% | ||
| -$91K+95.8% | -$1.09M— | -$4.8M— | $0-100% | -$2.16M-129% | ||
| $232K+7.4% | $228K— | $224K+6.7% | $221K+7.3% | $216K-63.5% | ||
| -$191K-17.9% | -$187K— | -$183K-17.3% | -$179K-17.8% | -$162K+38.9% | ||
| -$396K+47.1% | -$169K-77.9% | —— | -$490K-775% | -$748K-64.8% | ||
| -$12.52M+18.8% | -$12.2M+7.1% | -$20.48M-55.6% | -$13.89M+32.1% | -$15.42M+31.1% | ||
| $138K— | $31K+24.0% | $37K+147% | $9K+12.5% | $0-100% | ||
| $5.87M-74.6% | $12.85M-50.7% | $39.34M+1,252% | $18.16M-3.4% | $23.11M+8.3% | ||
| $17.5M-6.3% | $29.31M+46.5% | $19M-9.0% | $21.47M-15.9% | $18.69M-6.6% | ||
| $11.49M+360% | —— | -$20.38M-214% | —— | -$4.42M-226% | ||
| $0-100% | —— | —— | $17K— | $2K— | ||
| $142K+8.4% | $139K+8.6% | $136K+8.8% | $133K+8.1% | $131K+8.3% | ||
| -$142K-101% | $0-100% | $29.62M— | $17.9M+33.6% | $18.63M+141% | ||
| -$1.17M+3.9% | —— | -$11.24M— | $7.3M+2,375% | -$1.21M+92.4% | ||
| $17K-39.3% | $19K-36.7% | $22K-33.3% | $25K-30.6% | $28K-26.3% | ||
| $255K-51.2% | $361K-34.4% | $512K-15.9% | $458K-37.7% | $523K-35.5% | ||
| $1.31M+11.0% | $1.21M+56.8% | $1.31M+73.8% | $1.31M+79.5% | $1.18M+59.2% | ||
| -$191K-17.9% | -$187K— | -$183K-17.3% | -$179K-17.8% | -$162K+38.9% | ||
| -$396K+47.1% | -$169K-77.9% | —— | -$490K-775% | -$748K-64.8% | ||
| -$91K+95.8% | -$1.09M— | -$4.8M— | $0-100% | -$2.16M-129% | ||
| $232K+7.4% | $228K— | $224K+6.7% | $221K+7.3% | $216K-63.5% | ||
| $17.5M-6.3% | $29.31M+46.5% | $19M-9.0% | $21.47M-15.9% | $18.69M-6.6% | ||
| $142K+8.4% | $139K+8.6% | $136K+8.8% | $133K+8.1% | $131K+8.3% | ||
| $0-100% | $0-100% | $29.75M+148,665% | $17.93M+33.0% | $18.76M+139% | ||
| $0-100% | —— | —— | $17K— | $2K— | ||
| -$191K-17.9% | -$187K— | -$183K-17.3% | -$179K-17.8% | -$162K+38.9% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $15K-11.8% | —— | $31K— | —— | $17K-50.0% | ||
| -$12.66M+17.9% | -$12.23M+7.1% | -$20.51M-55.7% | -$13.9M+32.0% | -$15.42M+31.2% | ||
| -$12.66M+17.9% | -$12.23M+7.1% | -$20.51M-55.7% | -$13.9M+32.0% | -$15.42M+31.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does aTyr Pharma generate?
- aTyr Pharma (ATYR) generated -$59.1M in operating cash flow over the trailing twelve months.
- What is aTyr Pharma's free cash flow?
- After $215.0K of capital expenditures, aTyr Pharma's free cash flow was -$59.3M over the trailing twelve months, up 4.7% year over year.
- Where does aTyr Pharma's cash flow data come from?
- Every line is extracted from aTyr Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
